New blood test could end painful liver biopsies for millions

NCT ID NCT04616664

Completed Diagnosis Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information like age, weight, and diabetes status with blood markers and genetic data. If proven accurate, this test could make screening for liver disease much easier and safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LLIFT (Lille LIver Fat Test) – a blood test combining clinical data, lab values, and genetic markers
What this could lead to: If successful, this could provide a simple, non-invasive blood test to diagnose fatty liver disease and NASH, replacing the need for a liver biopsy in many patients.
What could go wrong: This is a diagnostic accuracy study, not a treatment trial. The test may not be accurate enough to replace biopsy in all cases, and results may not apply to lower-risk populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH - NONALCOHOLIC STEATOHEPATITIS OBESITY

Contacts and locations

Locations

CH ARRAS

Arras, France
CH LENS

Lens, France
CH de Douai

Douai, France
Ch Valenciennes

Valenciennes, France
Chu Amiens Picardie

Amiens, France
GHIRCL saint Philibert

Lomme, France
Hop Claude Huriez Chu Lille

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.